{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "LSE", "shortName": "ANAVEX LIFE SCIENCES CORP ANAVE", "longName": "Anavex Life Sciences Corp.", "messageBoardId": "finmb_13580387", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChangePercent": -3.337664, "regularMarketPrice": 8.92, "marketState": "CLOSED", "fiftyTwoWeekHighChangePercent": -0.39709362, "fiftyTwoWeekLow": 7.61, "fiftyTwoWeekHigh": 14.795, "earningsTimestamp": 1683635400, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.579, "sharesOutstanding": 45431300, "bookValue": 1.828, "fiftyDayAverage": 9.006745, "fiftyDayAverageChange": -0.08674526, "fiftyDayAverageChangePercent": -0.009631144, "twoHundredDayAverage": 9.995756, "twoHundredDayAverageChange": -1.0757561, "twoHundredDayAverageChangePercent": -0.10762128, "marketCap": 5130177, "priceToBook": 4.87965, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "priceHint": 2, "regularMarketChange": -0.3079996, "regularMarketTime": 1683907445, "regularMarketDayHigh": 9.115, "regularMarketDayRange": "8.92 - 9.115", "regularMarketDayLow": 8.92, "regularMarketVolume": 1090, "regularMarketPreviousClose": 9.228, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 9.105, "averageDailyVolume3Month": 1953, "averageDailyVolume10Day": 2567, "fiftyTwoWeekLowChange": 1.31, "fiftyTwoWeekLowChangePercent": 0.17214191, "fiftyTwoWeekRange": "7.61 - 14.795", "fiftyTwoWeekHighChange": -5.875, "firstTradeDateMilliseconds": 1517212800000, "symbol": "0HFR.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "630 5th Avenue", "address2": "20th Floor", "city": "New York", "state": "NY", "zip": "10111", "country": "United States", "phone": "844 689 3939", "website": "https://www.anavex.com", "industry": "", "sector": "", "longBusinessSummary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.", "fullTimeEmployees": 38, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher U. Missling M.B.A., M.S., Ph.D.", "age": 56, "title": "Chairman, Pres, CEO & Sec.", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 708600, "fmt": "708.6k", "longFmt": "708,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 39571984, "fmt": "39.57M", "longFmt": "39,571,984"}}, {"maxAge": 1, "name": "Ms. Sandra  Boenisch CPA, CPA, CGA", "age": 41, "title": "Principal Financial Officer & Treasurer", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 174900, "fmt": "174.9k", "longFmt": "174,900"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1436352, "fmt": "1.44M", "longFmt": "1,436,352"}}, {"maxAge": 1, "name": "Mr. Stephan  Toutain", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Walter E. Kaufmann M.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Clint  Tomlinson", "title": "VP of Corp.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Adebayo  Laniyonu Ph.D.", "title": "Sr. VP of Nonclinical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Edward R Hammond M.D., M.P.H., Ph.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kun  Jin Ph.D.", "title": "Head of Biostatistics", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}